CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT550

EST. COMPLETION2027-06-01

Conditions

Gastroesophageal-junction CancerMonoclonal AntibodyGastric CancerHER2-positive Gastric Cancer

Interventions

HLX22PembrolizumabTrastuzumabOxaliplatinCapecitabine

Study details

SPONSORShanghai Henlius Biotech

START DATE2024-11-22

Related company profiles

Shanghai Henlius Biotech

2696.HK

Primary source

ClinicalTrials.gov record NCT06532006 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06532006
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record